Cancer Patient Survival Rates

While we are proud to publicise our survival statistics for various common cancers, we don’t think of our patients as statistics. Our patients are individuals with specific needs and health complexities. No two patients fit in the same box.

Understanding Survival Rates

Statistics collected about any cancer don’t take into consideration information about individual cases. They do not consider age groups, whether a patient has had previous illness, the extent of cancer at diagnosis, complications experienced, previous treatments or adverse reactions to these treatments or any damage left behind by them. Also not taken into account are patients’ lifestyle choices or genetics.  

No one is living the same same cancer as someone else

Creating a statistic or success rate represents a linear approach to cancer, by just looking at this problem from the tumor view, without acknowledging each patient’s unique background.

Nonetheless, our numbers are meant to present a general understanding of what cancers we see and how successful our outcomes have been. More than 50% of our survivors live more than two years. 

Cancer Type Case Number Stage I Stage II Stage III Stage IV Benefit Rate (%)
Lung Cancer 1067 33 97 408 428 90%
Pancreatic Cancer 195 3 11 32 87 93%
Breast Cancer 125 2 3 16 67 88%
Ovarian Cancer 52 0 3 9 28 92%
Colon Cancer 47 0 1 5 28 87%
Lymphoma 40 2 9 8 4 93%
Cervical Cancer 24 1 1 5 12 96%
Bladder Cancer 11 0 1 0 4 100%

The graph below shows the number of months patients have survived after receiving any treatment at our Center.

Key:
CR= Complete Response | PR= Partial Response | SD=Stable | PD=Progress | Effect rate= CR+PR | Benefit Rate=CR+PR+SD

Including Stage 4 patients, over 90% of our patients have been in the 80-90% benefit rate.

Cancer Type Case Number Stage I Stage II Stage III Stage IV Not Staged CR PR SD PD Effect Rate (%) Benefit Rate (%)
Lung Cancer 1067 33 97 408 428 101 17 298 642 110 30 90
Pancreatic Cancer 195 3 11 32 87 62 0 14 168 13 7 93
Breast Cancer 125 2 3 16 67 37 3 33 74 15 29 88
Ovarian Cancer 52 0 3 9 28 12 0 12 36 4 23 92
Colon Cancer 47 0 1 5 28 13 0 7 34 6 15 87
Lymphoma 40 2 9 8 4 17 6 16 15 2 55 93
Cervical Cancer 24 1 1 5 12 5 3 3 17 1 25 96
Bladder Cancer 11 0 1 0 4 6 0 2 9 0 18 100
Esophageal Cancer 1085 10 313 363 341 58 55 242 711 77 27 93
Liver Cancer 463 8 96 121 103 135 0 81 351 31 18 93
Gastric Cancer 169 6 18 31 86 28 0 27 125 17 16 90
Rectal Cancer 133 4 12 8 47 62 0 23 98 12 17 91
Cardiac Cancer 110 1 14 32 40 23 2 26 74 8 25 93
Kidney Cancer 33 2 0 2 15 14 0 2 26 5 6 85
Thyroid Cancer 24 0 2 3 5 14 0 2 18 4 8 83
Hypopharyngeal Cancer 21 1 1 5 9 5 0 4 15 2 19 90
Nasopharyngeal Cancer 16 0 2 7 3 4 0 3 11 2 19 88
Endometrial Cancer 14 0 0 0 9 5 1 3 7 3 29 79
Laryngeal Cancer 11 0 0 2 4 5 0 2 7 2 18 82
Parotid Gland Cancer 10 0 0 0 5 5 0 3 6 1 30 90
Other Cancer 242 1 0 15 53 173 2 44 173 24 19 90
Total 3892 74 584 1072 1378 784 89 847 2617 339 24 91

Side Effects: No except fever

We’ve collected statistics about the benefits of our treatments for over 20 years and compared them to traditional treatments.

Indication Survival Rates Conventional Standard Care Intratumoral Chemoteraphy Our Treatments
(at least 1 of our treatments)
Advanced Pancreatic Cancer

(120 cases)

 6 Month Survival Rate (%) 27% 18% 77%
12 Month Survival Rate (%) 13% 9% 57%
Advanced Lung Cancer

(259 cases)

 6 Month Survival Rate (%) 39% 61% 95%
12 Month Survival Rate (%) 23% 33% 86%
2 Year Survival Rate (%) 11% 7% 37%
Liver Cancer

(221 cases)

 6 Month Survival Rate (%) NA 32% 61%
12 Month Survival Rate (%) 17% 19% 30%

Traditional survival rates sources: 

 

  1. “Use of Hapten Combined Cytotoxic Drugs for Enhancing Therapeutic Effect in Advanced Stages of Pancreatic Cancer,” Journal of Liver Research, Disorders & Therapy, December 30, 2015
  2. “Hapten Improved Overall Survival Benefit in Late Stages of Non-Small Cell Lung Cancer (NSCLC) by at least one of our Functional Oncology available treatments (Our Treatments), Therapy With and without Radiation Therapy,” Journal of Cancer Prevention & Current Research, February 8, 2016
  3. Journal of Hepatocellular Carcinoma, 2015:2 1-12 
  4. SEER data, based on compiled 2007-2013data